Table 4.
Concordance of randomized clinical trial outcomes
| Treatmenta | N | Primary end point (per-protocol) | Significant difference in CR | Significant difference in EFS/PFS | Significant difference in OS | Superior arm |
| Aggressive histology lymphoma | ||||||
| Dose-escalated CHOEP-21 versus CHOEP-21 [33] | 389 | EFS | No | No | No | No difference |
| R-CHOP-14 versus CHOP-14 for 6 versus 8 cycles [34] | 1222 | EFS | Yes | Yes | Yes | R-CHOP-14 for 6 cycles |
| CEOP-14 versus CEOP-21, ±R [35] | 217 | OS | No | n/a | No | No difference |
| Escalated R-CEOP versus escalated CEOP [36] | 204 | DFS | No | n/a | No | No difference |
| Intensified CHOP-14 for 6 cycles versus standard CHOP-21 for 8 cycles [37] | 477 | OS | No | No | No | No difference |
| Mini-COEP versus P-VEBEC [38] | 232 | OS | No | No | No | No difference |
| R-CHOP versus CHOP, then R-maintenance versus nothing [39] | 632 | EFS | n/a | Yes | No | R-CHOP |
| R-CHOP-like versus CHOP-like chemotherapy [34] | 824 | EFS | Yes | Yes | Yes | R-CHOP like |
| PMitCEBO versus CHOP, ±GCSF [40] | 784 | EFS | Yes | No | No | No difference |
| Flexible versus fixed dosing of anthracycline in ProMECE-CytaBOM or ProMI-CytaBOM [41] | 356 | EFS | No | n/a | No | No difference |
| ProMECE-CytaBOM versus ProMI-CytaBOM, then maintenance chemotherapy [42] | 249 | OS | No | No | No | No difference |
| R-CHOP-14 versus CHOP-14 [43] | 243 | EFS | n/a | n/a | Yes | R-CHOP |
| CIOP versus CHOP [44] | 211 | OS | Yes | Yes | Yes | CHOP |
| Pirarubicin-COP versus CHOP (2/3 dose) versus pirarubicin-COPE [45] | 443 | OS | No | No | No | No difference |
| VEPA-B/FEPP-AB/M-FEPA every 10 weeks for 3 cycles versus VEPA-B/FEPP-B/M-FEPA every 14 weeks for 4 cycles [46] | 447 | OS | No | n/a | No | No difference |
| CHOP-14 versus CHOP-21, ±etoposide [47] | 689 | EFS | n/a | Yes | No | CHOP-14 |
| ACVBP versus CHOP [26] | 635 | EFS | No | Yes | Yes | ACVBP |
| CHOEP versus CHOP, every 14 versus 21 days [48] | 710 | EFS | n/a | Yes | No | CHOEP |
| CNOP versus CHOP, ±GCSF [49] | 458 | EFS | Yes | Yes | Yes | CHOP |
| R-CHOP versus CHOP [50] | 399 | EFS | Yes | Yes | Yes | R-CHOP |
| CNOP versus CEOP [51] | 249 | OS | No | No | No | No difference |
| PMitCEBO versus PAdriaCEBO [52] | 473 | OS | No | n/a | Yes | PMitCEBO |
| CHOP + IFN versus CHOP [53] | 435 | RR | No | n/a | No | No difference |
| PACEBOM versus CHOP [54] | 459 | OS | No | n/a | No | No difference |
| MACOP-B versus CHOP [55] | 374 | OS | No | No | No | No difference |
| CAPOMEt versus CHOP-MTX [56] | 281 | OS | No | n/a | No | No difference |
| MECOP-B versus MACOP-B [57] | 211 | OS | No | n/a | No | No difference |
| Alternating B-CHOP-M and PEEC-M versus B-CHOP-M [58] | 325 | OS | No | n/a | No | No difference |
| CTVmP versus CVmP [59] | 453 | OS | Yes | Yes | Yes | CTVmP |
| MACOP-B over CHOP [60] | 236 | CR | No | Yes | Yes | MACOP-B |
| ProMACE-MOPP versus MACOP-B [61] | 221 | OS | No | No | No | No difference |
| ProMECE-CytaBOM versus MACOP-B [62] | 210 | OS | No | No | No | No difference |
| m-BACOD versus CHOP versus ProMACE-CytaBOM versus MACOP-B [63] | 899 | OS | No | No | No | No difference |
| ProMACE-MOPP versus CHVmP-VB [64] | 430 | OS | n/a | No | No | No difference |
| Escalated BACOP versus BACOP [65] | 238 | OS | No | No | No | No difference |
| m-BACOD versus CHOP [66] | 325 | OS | No | No | No | No difference |
| F-MACHOP versus MACOP-B [67] | 286 | CR | No | n/a | No | No difference |
| Low-dose bleomycin + CHOP versus CHOP, then low versus high-dose MTX [68] | 177 | RR | No | No | No | No difference |
| Indolent histology lymphoma | ||||||
| R-CVP versus CVP [21] | 321 | EFS | Yes | Yes | Yes | R-CVP |
| R-CHVP + IFN versus CHVP-IFN [22] | 360 | EFS | Yes | Yes | No | R-CHVP + IFN |
| R-MCP versus MCP [20] | 358 | RR | Yes | Yes | Yes | R-MCP |
| CID versus CD [69] | 200 | EFS | No | Yes | No | CID |
| MCP versus CHOP [25] | 277 | CR | No | n/a | No | No difference |
| F versus CVP [23] | 381 | PFS | Yes | No | No | No difference |
| FMD versus CMD [70] | 400 | PFS | No | n/a | n/a | CMD |
| R-CHOP versus CHOP [71] | 428 | EFS | No | Yes | Yes | R-CHOP |
| CHOP + bleomycin versus cyclophosphamide [72] | 228 | OS | No | No | No | No difference |
| COPA + IFN versus COPA [73] | 291 | PFS | No | Yes | COPA + IFN | |
| PmM versus COP, then IFN-maintenance versus observation [74] | 246 | RR | Yes | n/a | n/a | Not available |
| CHOP versus chlorambucil + prednisone [24] | 259 | RR | n/a | Yes | No | No difference |
| CHVP + IFN versus CHVP [75] | 242 | PFS | No | Yes | Yes | CHVP + IFN |
| BOP versus COP [76] | 164 | CR | No | n/a | No | No difference |
| Cladribine versus CVP versus cladribine + C [77] | 197 | PFS | Yes | Yes | n/a | Cladribine |
| FM versus mini-CHVdP [78] | 155 | CR | Yes | Yes | No | FM |
| FND versus alternating triple therapy (CHOD-bleomycin, ESHAP, and NOPP) [79] | 142 | RR | No | Yes | No | No difference |
| CHVmP + IFN versus F [80] | 131 | EFS | No | n/a | n/a | CHVP + IFNb |
| CVP + IFN versus CVP, then IFN-maintenance versus observation [81] | 155 | RR | n/a | Yes | No | No difference |
| IFN versus prednimustine versus observation [59] | 193 | OS | No | No | No | No difference |
Bolded items represent the two comparator arms used for analysis in the following format: experimental versus standard arm.
Conclusion based on 2-year follow-up data.
RR, response rate; CR, complete response; EFS, Event-Free Survival; PFS, Progression-Free Survival; OS, overall survival; n/a, not applicable; CHOEP, cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CEOP, cyclophosphamide, epirubicin, vincristine, prednisone; R, rituximab; 14, cycle given every 14 days; 21, cycle given every 21 days; P-VEBEC, prednisone, vinblastine, epirubicin, bleomycin, etoposide, cyclophosphamide; PMitCEBO, prednisolone, mitoxantrone, cyclophosphamide, etoposide, bleomycin, vincristine; ProMECE-CytaBOM, prednisone, cyclophosphamide, etoposide, epidoxorubicin, cytarabine, bleomycin, vincristine, methotrexate with leucovorin; ProMICE-CytaBOM, prednisone, cyclophosphamide, etoposide, idarubicin, cytarabine, bleomycin, vincristine, methotrexate with leucovorin; CIOP, cyclophosphamide, idarubicin, vincristine, prednisone; COP or CVP, cyclophosphamide, vincristine, prednisolone (or prednisone); COPE, cyclophosphamide, vincristine, prednisolone, etoposide; VEPA-B/FEPP-AB/M-FEPA and VEPA-B/FEPP-B/M-FEPA both contain vincristine, cyclophosphamide, prednisolone, doxorubicin, bleomycin, etoposide, procarbazine, methotrexate, leucovorin, vindesine (at differing doses and schedules of administration); ACVBP, doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone; CNOP, cyclophosphamide, mitoxantrone, vincristine, prednisone; PAdriaCEBO, prednisolone, adriamycin, cyclophosphamide, etoposide, bleomycin, vincristine; IFN, interferon; GCSF, granulocyte colony stimulating factor; MTX, methotrexate; PACEBOM, prednisolone, doxorubicin, cyclophosphamide, etoposide, bleomycin, vincristine, methotrexate; MACOP-B, methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin; CAPOMEt, weekly alternating cyclophosphamide and doxorubicin, vincristine and prednisolone, methotrexate with leucovorin and etoposide; MECOP-B, methotrexate, epirubicin, cyclophosphamide, vincristine, prednisolone, and bleomycin; B-CHOP-M, bleomycin, cyclophosphamide, doxorubicin, vincristine, prednisolone and methotrexate; PEEC-M, methylprednisolone, vindesine, etoposide, chlorambucil and methotrexate; CVmP, cyclophosphamide, teniposide, prednisone; CTVmP, cyclophosphamide, pirarubicin, teniposide, prednisone; ProMACE-MOPP, procarbazine, methotrexate with leucovorin, doxorubicin, cyclophosphamide, and etoposide; m-BACOD, low-dose methotrexate with leucovorin rescue, bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone; ProMACE-CytaBOM, prednisone, doxorubicin, cyclophosphamide, and etoposide, followed by cytarabine, bleomycin, vincristine, and methotrexate with leucovorin rescue; CHVmP-VB, cyclophosphamide, doxorubicin, teniposide, prednisone and vincristine, bleomycin; BACOP, bleomycin, doxorubicin, cyclophosphamide, vincristine, prednisone; m-BACOD, bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone, methotrexate with leucovorin; F-MACHOP, 5-fluorouracil, methotrexate with leucovorin, cytarabine, cyclophosphamide, doxorubicin, vincristine, prednisone; CHVP, cyclophosphamide, doxorubicin, etoposide, prednisolone; MCP, mitoxantrone; chlorambucil, prednisolone; CID, chlorambucil, idarubicin, dexamethasone; CD, chlorambucil, dexamethasone; F, fludarabine; CMD, chlorambucil, mitoxantrone, dexamethasone; FMD, fludarabine, mitoxantrone, dexamethasone; COPA, cyclophosphamide, doxorubicin, vincristine and prednisone every 28 days; PmM, prednimustine, mitoxantrone; BOP, bendamustine, vincristine, prednisone; FM, fludarabine, mitoxantrone; CHVdP, cyclophosphamide, doxorubicin, vindesine, prednisone; FND, fludarabine, mitoxantrone, dexamethasone; CHOD, cyclophosphamide, doxorubicin, vincristine, dexamethasone, bleomycin; ESHAP, etoposide, methylprednisolone, cytarabine, cisplatin; NOPP, mitoxantrone, vincristine, procarbazine, prednisone.